Map claims to evidence strength, expert review status, uncertainty, and revision history. Confidence states: preliminary → evidence-backed → expert-reviewed → revised.
| Claim | Evidence | Expert status | Uncertainty | Confidence | Sources | Share |
|---|---|---|---|---|---|---|
| Potency assay ambiguity remains one of the central bottlenecks in therapeutic EV development. Without a mechanism-linked potency assay, batch release and comparability are weakened. | High | pending | Medium | evidence backed | ||
| Local and topical EV applications may be more practical than broad systemic regenerative EV therapy. Delivery route and exposure drive CMC burden and clinical feasibility. | Medium | pending | Low-medium | evidence backed | ||
| Engineered EV delivery platforms must demonstrate clear advantage over LNP, AAV, and other established delivery modalities. Capital and development timelines require differentiated delivery economics and biodistribution. | High | pending | Medium | preliminary | ||
| Unapproved exosome clinic products carry significant regulatory and patient-safety risk and are not a credible venture pathway. Therapeutic claims require IND-enabled GMP development, not cash-pay clinic economics. | High | documented | Low | evidence backed | ||
| EV manufacturing is improving but remains a CMC-heavy, non-commodity process—not plug-and-play biologics manufacturing. COGS, facility design, and comparability drive venture capital intensity and timeline risk. | High | pending | Medium | evidence backed | ||
| Isolation and purification method largely defines the therapeutic EV product identity. Process changes without comparability data are regulatory and investment red flags. | High | pending | Low | evidence backed |
EV manufacturing is improving but remains a CMC-heavy, non-commodity process—not plug-and-play biologics manufacturing.
COGS, facility design, and comparability drive venture capital intensity and timeline risk.
Ahn SH et al. (2022). Manufacturing Therapeutic Exosomes: from Bench to Industry
Discusses cell line development, upstream culture, downstream purification, formulation, and GMP challenges for clinical-grade exosome therapeutics.
Open source →Supports claims: ev_manufacturing_not_plug_and_play
Gimona M et al. (2017). Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use
Requirements for manufacturing, safety, and efficacy testing of EV therapeutics from laboratory to patient; MSC-EV translational strategies.
Open source →Supports claims: potency_assay_ambiguity, ev_manufacturing_not_plug_and_play, local_topical_more_practical
Falcon-Perez JM et al. (2025). Advancing translational potential of EVs through ISEV-TRA
ISEV Translation, Regulation and Advocacy Committee addresses regulatory uncertainty and manufacturing barriers to EV commercialization.
Open source →Supports claims: ev_manufacturing_not_plug_and_play
Example only: reviewers often flag potency assays that measure generic immunomodulation without linkage to intended MOA in the target indication.
No revisions yet. Revisions will appear after expert feedback updates claim text.